181 related articles for article (PubMed ID: 9987141)
21. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
[TBL] [Abstract][Full Text] [Related]
22. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
[TBL] [Abstract][Full Text] [Related]
23. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis.
Dell'Era L; Corona F; Daleno C; Scala A; Principi N; Esposito S
Vaccine; 2012 Jan; 30(5):936-40. PubMed ID: 22138210
[TBL] [Abstract][Full Text] [Related]
25. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.
Kumar D; Campbell P; Hoschler K; Hidalgo L; Al-Dabbagh M; Wilson L; Humar A
Transplantation; 2016 Mar; 100(3):662-9. PubMed ID: 26335915
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis.
Beyer WE; Nauta JJ; Palache AM; Giezeman KM; Osterhaus AD
Vaccine; 2011 Aug; 29(34):5785-92. PubMed ID: 21624411
[TBL] [Abstract][Full Text] [Related]
27. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
[TBL] [Abstract][Full Text] [Related]
28. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
29. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (®) adjuvant: results from a dose-finding clinical trial in older adults.
Della Cioppa G; Nicolay U; Lindert K; Leroux-Roels G; Clement F; Castellino F; Galli G; Groth N; Del Giudice G
Hum Vaccin Immunother; 2012 Feb; 8(2):216-27. PubMed ID: 22426371
[TBL] [Abstract][Full Text] [Related]
30. Superior protection provided by a single dose of MF59-adjuvanted whole inactivated H5N1 influenza vaccine in type 1 diabetic mice.
Wu J; Wang F; Fang F; Zhang W; Chang H; Zheng L; Chen Z
Arch Virol; 2011 Mar; 156(3):387-95. PubMed ID: 21110049
[TBL] [Abstract][Full Text] [Related]
31. Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.
Johnson C; Hohenboken M; Poling T; Jaehnig P; Kanesa-Thasan N
J Infect Dis; 2015 Jul; 212(1):72-80. PubMed ID: 25538277
[TBL] [Abstract][Full Text] [Related]
32. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
[TBL] [Abstract][Full Text] [Related]
34. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
O'Hagan DT
Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
[TBL] [Abstract][Full Text] [Related]
35. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects.
de Bruijn IA; Nauta J; Gerez L; Palache AM
Vaccine; 2006 Nov; 24(44-46):6629-31. PubMed ID: 16901593
[TBL] [Abstract][Full Text] [Related]
36. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age.
Arguedas A; Soley C; Abdelnour A; Sales V; Lindert K; Della Cioppa G; Clemens R;
Hum Vaccin; 2011 Jan; 7(1):58-66. PubMed ID: 21285531
[TBL] [Abstract][Full Text] [Related]
37. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
[TBL] [Abstract][Full Text] [Related]
38. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
39. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
[TBL] [Abstract][Full Text] [Related]
40. A 21-winter seasons retrospective study of antibody response after influenza vaccination in elderly (60-85 years old) and very elderly (>85 years old) institutionalized subjects.
Nunzi E; Iorio AM; Camilloni B
Hum Vaccin Immunother; 2017 Nov; 13(11):2659-2668. PubMed ID: 28922621
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]